Status:
COMPLETED
Astaxanthin (2 mg) + Lycopene (1.8 mg) + D-Alpha-Tocopherol (10 IU) For The Treatment Of Skin Aging
Lead Sponsor:
United Laboratories
Conditions:
Skin Aging
Wrinkles
Eligibility:
All Genders
30-60 years
Phase:
NA
Brief Summary
The purpose of this study is to determine the clinical efficacy of a combination of Astaxanthin (2 mg), Lycopene (1.8 mg), and d-alpha-Tocopherol (10 IU) in terms of its skin anti-aging properties. Sp...
Eligibility Criteria
Inclusion
- Healthy individuals age 30 to 60 years old
- Fitzpatrick Skin Type I-IV
- Crow's Feet Wrinkle Scale Class 1-2
- Subjects willing to provide written informed consent
Exclusion
- Use of topical or oral anti-aging drug therapy 1 month prior to the study
- History of allergy to cosmetics and anti-aging drugs
- History of photosensitivity reactions
- Any current or past medical condition, including seizures and stroke
- History of pigmentation disorder such as but not limited to vitiligo and leukoderma
- Immunocompromised state
- Pregnant or lactating (pregnancy kit will be used to check)
- Patients who have undergone laser, radiofrequency, peeling, and other procedural therapies for anti-aging in the month prior to the study.
- Patients with current inflammatory or infectious skin disease on the face, or history of such in the month prior to the study.
- Patients taking OCDs and other photosensitizing drugs (e.g. tetracycline).
- Not willing to provide informed consent
Key Trial Info
Start Date :
March 5 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 7 2019
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT03460860
Start Date
March 5 2018
End Date
February 7 2019
Last Update
June 26 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PDC Building, 1440 Taft Avenue
Manila, National Capital Region, Philippines